Cargando…

A unique case of dermatomyositis associated with anti-TIF1γ antibody and chondrosarcoma

Detalles Bibliográficos
Autores principales:	Dziwis, Jennifer, Agnihothri, Ritesh, Lieberman, Alicia, Richardson, Christopher T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731355/ https://www.ncbi.nlm.nih.gov/pubmed/31517008 http://dx.doi.org/10.1016/j.jdcr.2019.07.024

Ejemplares similares

Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
por: Nakanishi, Yu, et al.
Publicado: (2020)

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
por: Harada, Yumi, et al.
Publicado: (2022)

1. TIF1-γ associated dermatomyositis
por: Waller, Rosemary, et al.
Publicado: (2019)

Marked Improvement of Anti-TIF1-γ Antibody-Positive Dermatomyositis After Chemoradiotherapy to Relevant Nasopharyngeal Cancer
por: Tomita, Natsuo, et al.
Publicado: (2021)

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
por: Lerman, Irina, et al.
Publicado: (2019)

Prominent dyspigmentation in a patient with dermatomyositis and TIF1-γ autoantibodies
por: Gutierrez, Daniel, et al.
Publicado: (2022)

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
por: Imai, Ryosuke, et al.
Publicado: (2021)

Dermatomyositis with positive anti‐TIF1 gamma antibodies in an adult female: A case report
por: Adhikari, Krishna, et al.
Publicado: (2023)

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report
por: Kubeček, Ondřej, et al.
Publicado: (2016)

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis
por: Wu, Chih-Feng, et al.
Publicado: (2023)

Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2021)

Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
por: Karino, Kohei, et al.
Publicado: (2018)

A case of dermatomyositis with anti-TIF1γ antibodies revealing isolated para-aortic lymphadenopathy metastatic recurrence of endometrial cancer: A case report
por: Lim, Darosa, et al.
Publicado: (2020)

NanoString technology distinguishes anti‐TIF‐1γ(+) from anti‐Mi‐2(+) dermatomyositis patients
por: Preusse, Corinna, et al.
Publicado: (2021)

Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature
por: Ono, Ryohei, et al.
Publicado: (2021)

Clinical characteristics of patients with anti-TIF1-γ antibodies
por: Masiak, Anna, et al.
Publicado: (2016)

Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor
por: Zhang, Hengzhe, et al.
Publicado: (2023)

The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature
por: Zarkavelis, George, et al.
Publicado: (2020)

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis
por: Li, Xiaomeng, et al.
Publicado: (2022)

A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels
por: Akagi, Hideko, et al.
Publicado: (2023)

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis
por: Parkes, Joanna E., et al.
Publicado: (2018)

Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence
por: Ferronato, Marco, et al.
Publicado: (2023)

Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
por: Satoh, Minoru, et al.
Publicado: (2012)

The Roles of TIF1γ in Cancer
por: Yu, Chengpeng, et al.
Publicado: (2019)

A case of concurrent systemic sclerosis and scleredema
por: Mitchell, Drew C., et al.
Publicado: (2019)

An atypical clinical presentation of alopecia in 2 patients with systemic lupus erythematosus
por: Lerman, Irina, et al.
Publicado: (2019)

AB019. Response to tofacitinib in a case of refractory TIF-1 positive amyopathic dermatomyositis with arthritis
por: Jasmine, Sion Ward, et al.
Publicado: (2021)

ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis
por: Selickaja, Sandra, et al.
Publicado: (2022)

Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
por: Mariscal, Anaís, et al.
Publicado: (2021)

Wong-type dermatomyositis with interstitial lung disease and anti-SRP and -PM/Scl antibodies treated with intravenous immunoglobulin
por: Kowalski, Eric H., et al.
Publicado: (2023)

Myositis-specific Autoantibodies Reacting to Both Tif1gamma and Mi-2 in a Patient with Juvenile Dermatomyositis
por: TAKEZAKI, Daiki, et al.
Publicado: (2020)

Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
por: Kurushima, Shota, et al.
Publicado: (2017)

AB023. An atypical clinical presentation of alopecia in two patients with systemic lupus erythematosus
por: Lerman, Irina, et al.
Publicado: (2021)

NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation
por: Butt, Zeeshan, et al.
Publicado: (2017)

A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies
por: Ito, Mitsuru, et al.
Publicado: (2020)

A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing
por: Mulhearn, Ben, et al.
Publicado: (2022)

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer
por: Sato, Yuki, et al.
Publicado: (2022)

Dynamic Regulation of Tgf-B Signaling by Tif1γ: A Computational Approach
por: Andrieux, Geoffroy, et al.
Publicado: (2012)

A Case of Anti-SAE1 Dermatomyositis
por: de Vries, Max, et al.
Publicado: (2022)

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy
por: Aritomi, Takafumi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_16ovgro490stehrhkngttsghm0